BRVE

20.3905.81%
MA

Michele A. Anderson

Chief Development Officer

Ms. Michele A. Anderson serves as Chief Development Officer at Braveheart Bio, Inc. since October 2025. She served as Senior Vice President, Regulatory Affairs at Human Immunology Biosciences, Inc. She served as Chief Development Officer at Assembly Biosciences, Inc. since August 01, 2022 until 2023 and served as its Senior Vice President of Development Operations since September 2021 until August 01, 2022. and served as its Senior Vice President of Regulatory Affairs and Quality Assurance since December 2019 until September 2021. Ms. Anderson joined Assembly from Gilead Sciences, Inc., where she served as Executive Director, Regulatory Affairs and was responsible for global development programs in viral hepatitis, inflammation and oncology. Her achievements include the development and approvals of Vemlidy® for HBV and of Sovaldi®, Harvoni®, Epclusa® and Vosevi® for HCV in the U.S. and globally, including Asia. She brings clinical, nonclinical and CMC regulatory affairs experience, as well as QA and QC, Paragraph IV generic drug development, across multiple dosage forms including solid oral dosage forms, injectables and transdermals. In 2019, she was named one of the most influential women in Bay Area business by the San Francisco Bay Times. Prior to joining Gilead, Ms. Anderson held various regulatory affairs positions at CV Therapeutics, IMPAX Laboratories and Cygnus. Ms. Anderson earned a BS in Biological Sciences from California Polytechnic State University, San Luis Obispo.

Positions